Table A36:
Probabilistic Analyses, Scenarios
| Scenarios | Reference Case | Scenarios |
|---|---|---|
| Time horizon | Time horizon: 1 y Discounting: 0% |
Time horizons: 6 mo, 2 y, 3 y, and 5 y Discounting: 1.5% for time horizons > 1 y Effectiveness of PGx: Constant over first 2 years and declines to effectiveness of usual treatment from year 3 One relapse modeled over time horizon All parameter inputs were same as in reference case Additional analyses were performed for each time horizon (6 mo, 2 y, 3 y, and 5 y) with the RR of relapse (intervention) = 1 |
| Well health state | Not included | Well state included in these scenarios |
| Analytic perspective: inclusion of non-medical and indirect costsa | MOH perspective: solely direct medical costs | Analysis 1 : inclusion of social services: non-medical direct costs paid by Canadian government87: $1,522 (SD: $4,176) in no remission, and $510 (SD: $2,507) in remission, yearly (2018 CAD) Analysis 2: inclusion of social services costs paid by government (analysis 1)87 plus costs by private payer for disability claims, no remission159: annual short-term disability claimed costs of $6,263 (2011 CAD, N = 79) and $7,832 (2012 CAD, N = 86) and annual long-term disability claimed costs of $13,598 (2011 CAD, N = 80) and $13,927 (2012 CAD, N = 89)b Analysis 3: social perspective, inclusion of social services costs,87 costs of disability,159 and costs related to absenteeism and productivity loss85: $3,219 (SD:$6,587, N = 9,990, 2010 USD) in no remission and $1,191 (SD: $2,391, N = 9,990, 2010 USD) in remission |
Abbreviations: PGx, multi-gene pharmacogenomic testing; RR, risk ratio; SD, standard deviation; CAD, Canadian dollar; N; sample size.
a
Cost estimates were as reported in original papers. Cost inputs were transferred to 2020 CAD, using the Canadian Consumer Price Index (CPI).
b
Average per-person claimed costs were calculated (2011 CAD estimates were transformed into 2012 CAD using CPI); SEs were assumed to be 25% of mean.